Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

No Evidence of Association of the Arg72Pro p53 Gene Polymorphism with Cancer Risk in the Saudi Population: a Meta-Analysis

  • Published : 2015.09.02
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Earlier studies on the association between p53 codon 72 Arg>Pro polymorphism and cancer risk were inconclusive and conflicting for the Saudi population. Therefore, we performed a meta-analysis to investigate the relationship between the codon 72 Arg>Pro polymorphism and overall cancer risk in Saudi Arabia. Materials and Methods: We searched all eligible published studies and data were pooled together to perform the meta-analysis. Pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated for homozygous, heterozygous, dominant and recessive genetic models. Results: A total of five eligible published studies covering 502 cancer cases and 784 healthy controls were included in the meta-analysis. No publication bias was detected in this study. The results suggested that the variant (Pro vs Arg: p=0.960; OR=1.004, 95% CI=0.852-1.183), homozygous (Pro.Pro vs Arg.Arg: p=0.970; OR=1.006, 95% CI=0.729-1.390), heterozygous (Arg.Pro vs Arg.Arg: p=0.473; OR=0.783, 95% CI=0.402-1.527) carriers were not associated with overall cancer risk. Similarly, dominant (Pro.Pro+Pro.Arg vs Arg.Arg: p=0.632; OR=0.886, 95% CI=0.540-1.454) and recessive (Pro.Pro vs Pro.Arg+Arg.Arg: p=0.269; OR=1.163, 95%CI=0.890-1.521) models also did not indicate increased risk of cancer. Conclusions: The current meta-analysis suggests that the codon 72 Arg>Pro polymorphism of the p53 gene might not contribute to cancer susceptibility in Saudi population. Future well designed large case control studies are needed to validate our findings.

Keywords

References

  1. Aizat AA, Shahpudin SN, Mustapha MA, et al (2011). Association of Arg72Pro of P53 polymorphism with colorectal cancer susceptibility risk in Malaysian population. Asian Pac J Cancer Prev, 12, 2909-13.
  2. Al-Fatlawi AA, Al-Fatlawi AA, Irshad M, et al (2014). Rice bran phytic acid induced apoptosis through regulation of Bcl-2/Bax and p53 genesin HepG2 human hepatocellular carcinoma cells. Asian Pac J Cancer Prev, 15, 3731-6. https://doi.org/10.7314/APJCP.2014.15.8.3731
  3. Al-Hadyan KS, Al-Harbi NM, Al-Qahtani SS, et al (2012). Involvement of single-nucleotide polymorphisms in predisposition to head and neck cancer in Saudi Arabia. Genet Test Mol Biomarkers, 16, 95-101. https://doi.org/10.1089/gtmb.2011.0126
  4. Al-Qasem A, Toulimat M, Tulbah A, et al (2012). The p53 codon 72 polymorphism is associated with risk and early onset of breast cancer among Saudi women. Oncol Lett, 3, 875-8.
  5. Alsbeih G, Al-Harbi N, Al-Hadyan K, et al (2010). Association between normal tissue complications after radiotherapy and polymorphic variations in TGFB1 and XRCC1 genes. Radiat Res, 173, 505-11. https://doi.org/10.1667/RR1769.1
  6. Alsbeih G, Al-Harbi N, El-Sebaie M, et al (2013). HPV prevalence and genetic predisposition to cervical cancer in Saudi Arabia. Infect Agent Cancer, 8, 1-15. https://doi.org/10.1186/1750-9378-8-1
  7. Alshatwi AA, Hasan TN, Shafi G (2012). A single-nucleotide polymorphism in the TP53 and MDM-2 gene modifies breast cancer risk in an ethnic Arab population. Fundam Clin Pharmacol, 26, 438-43. https://doi.org/10.1111/j.1472-8206.2011.00939.x
  8. Saudi Cancer Registry (2014). http://www.scr.org.sa
  9. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
  10. Dunna NR, Vure S, Sailaja K, et al (2012). TP53 codon 72 polymorphism and risk of acute leukemia. Asian Pac J Cancer Prev, 13, 347-50. https://doi.org/10.7314/APJCP.2012.13.1.349
  11. Egger M, Davey-Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
  12. Grochola LF, Zeron-Medina J, Meriaux S, et al (2010). Singlenucleotide polymorphisms in the p53 signaling pathway. Cold Spring Harb Perspect Biol, 2, a001032.
  13. Higgins JP, Thompson SG, Deeks JJ (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60. https://doi.org/10.1136/bmj.327.7414.557
  14. Hou J, Jiang Y, Tang W, et al (2013) p53 codon 72 polymorphism and breast cancer risk: A meta-analysis. Exp Ther Med, 5, 1397-402.
  15. Hrstka R, Coates PJ, Vojtesek B (2009). Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment. J Cell Mol Med, 13, 440-53. https://doi.org/10.1111/j.1582-4934.2008.00634.x
  16. Jemal A, Bray F, Center MM (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  17. Kafshdooz T, Tabrizi AD, Mohaddes Ardabili SM, et al (2014). Polymorphism of p53 gene codon 72 in endometrial cancer: correlation with tumor grade and histological type. Asian Pac J Cancer Prev, 15, 9603-6. https://doi.org/10.7314/APJCP.2014.15.22.9603
  18. Katkoori VR, Jia X, Shanmugam C, et al (2009). Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma. Clin Cancer Res, 15, 2406-16. https://doi.org/10.1158/1078-0432.CCR-08-1719
  19. Levine AJ, Oren M (2009). The first 30 years of p53: growing ever more complex. Nat Rev Cancer, 9, 749-58. https://doi.org/10.1038/nrc2723
  20. Lin HY, Huang CH, Wu WJ, et al (2008). TP53 codon 72 gene polymorphism paradox in associated with various carcinoma incidences, invasiveness and chemotherapy responses. Int J Biomed Sci, 4, 248-54.
  21. Liu L, Zhang D, Jiao JH, et al (2014). Association between the TP53BP1 rs2602141 A/C polymorphism and cancer risk: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 15, 2917-22. https://doi.org/10.7314/APJCP.2014.15.6.2917
  22. Mandal RK, Yaday SS, Panda AK, et al (2013). Insertion/deletion polymorphism of the ACE gene increased risk of Behcet disease: evidence from a meta-analysis. Ann Saudi Med, 33, 437-42.
  23. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  24. Murphy ME (2006). Polymorphic variants in the p53 pathway. Cell Death Differ, 13, 916-20. https://doi.org/10.1038/sj.cdd.4401907
  25. Nassiri M, Kooshyar MM, Roudbar Z, et al (2013). Genes and SNPs associated with non-hereditary and hereditary colorectal cancer. Asian Pac J Cancer Prev, 14, 5609-14. https://doi.org/10.7314/APJCP.2013.14.10.5609
  26. Pathak A, Wenzlaff AS, Hyland PL, et al (2014). Apoptosisrelated Single Nucleotide Polymorphisms and the risk of non-small cell lung cancer in women. J Cancer Ther Res, 3.
  27. Pharoah PD, Dunning AM, Ponder BA, et al (2004). Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer, 4, 850-60. https://doi.org/10.1038/nrc1476
  28. Pouladi N, Kouhsari SM, Feizi MH, et al (2014). Lack of association of intron 3 16 bp polymorphism of TP53 with breast cancer among Iranian-Azeri patients. Asian Pac J Cancer Prev, 15, 2631-4. https://doi.org/10.7314/APJCP.2014.15.6.2631
  29. Rao AK, Vinothkumar V, Revathidevi S, et al (2014). Absence of the TP53 Poly-A signal sequence variant rs78378222 in oral, cervical and breast cancers in south India. Asian Pac J Cancer Prev, 15, 9555-6. https://doi.org/10.7314/APJCP.2014.15.21.9555
  30. Rivlin N, Brosh R, Oren M, et al (2011). Mutations in the p53 tumor suppressor gene important milestones at the various steps of tumorigenesis. Genes Cancer, 2, 466-74. https://doi.org/10.1177/1947601911408889
  31. Shin MK, Kim JW (2014). Clinicopathologic and diagnostic significance of p53 protein expression in papillary thyroid carcinoma. Asian Pac J Cancer Prev, 15, 2341-4. https://doi.org/10.7314/APJCP.2014.15.5.2341
  32. Siraj AK, Al-Rasheed M, Ibrahim M, et al (2008). RAD52 polymorphisms contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population. J Endocrinol Invest, 31, 893-9. https://doi.org/10.1007/BF03346438
  33. Suzuki K, Matsubara H (2011). Recent advances in p53 research and cancer treatment. J Biomed Biotechnol, 2011, 978312.
  34. Verit FF, Yucel O (2013). Endometriosis, leiomyoma and adenomyosis: the risk of gynecologic malignancy. Asian Pac J Cancer Prev, 14, 5589-97. https://doi.org/10.7314/APJCP.2013.14.10.5589
  35. Vijayaraman KP, Veluchamy M, Murugesan P, et al (2012). p53 exon 4 (codon 72) polymorphism and exon 7 (codon 249) mutation in breast cancer patients in southern region (Madurai) of Tamil Nadu. Asian Pac J Cancer Prev, 13, 511-6. https://doi.org/10.7314/APJCP.2012.13.2.511
  36. Vineis P (2004). Individual susceptibility to carcinogens. Oncogene, 23, 6477-83. https://doi.org/10.1038/sj.onc.1207897
  37. Wang F, Wang P, Wang B, et al (2014). Association between TP53 Arg72Pro polymorphism and thyroid carcinoma risk. Tumour Biol, 35, 2723-8. https://doi.org/10.1007/s13277-013-1359-x
  38. Wu R, Li B (1999). A multiplicative-epistatic model for analyzing inter specific differences in out crossing species. Biometrics, 55, 355-65. https://doi.org/10.1111/j.0006-341X.1999.00355.x
  39. Xia LY, Zeng XT, Li C, et al (2013). Association between p53 Arg72Pro polymorphism and the risk of human papillomavirus-related head and neck squamous cell carcinoma: a meta-analysis. Asian Pac J Cancer Prev, 14, 6127-30. https://doi.org/10.7314/APJCP.2013.14.10.6127
  40. Xiang B, Mi YY, Li TF, et al (2012). Updated meta-analysis of the TP53 Arg72Pro polymorphism and gastric cancer risk. Asian Pac J Cancer Prev, 13, 1787-91. https://doi.org/10.7314/APJCP.2012.13.5.1787
  41. Zhou X, Gu Y, Zhang SL (2012). Association between p53 codon 72 polymorphism and cervical cancer risk among Asians: a HuGE review and meta-analysis. Asian Pac J Cancer Prev, 13, 4909-14. https://doi.org/10.7314/APJCP.2012.13.10.4909